••• MANN ENT ANNOUNCEMENT •••
We now offer the CareStart Covid Antigen Test with results returned in 10 minutes while you wait
PROPEL & SINUVA
DRUG ELUTING SINUS IMPLANTS
Mann ENT is pleased to offer patients the most cutting-edge technologies in the United States when it comes to those suffering from chronic sinusitis in the Raleigh, NC and surrounding areas. Over 37 million Americans suffer from chronic sinusitis every year- a condition that is marked by inflammation of the sinuses that causes the blocking of the nasal passages that can lead to chronic infections. Symptoms include sinus pain and pressure, loss of smell and taste, nasal congestion, headache, fatigue, nasal discharge, and depression. Typical treatment for sinusitis includes medications, systemic steroids, and sinus surgery. Mann ENT utilizes the latest advancement in treatment options like PROPEL and SINUVA for their patients suffering from chronic sinusitis to help improve clinical outcomes, promote proper healing, reduce the need for oral steroids, as well as extend results for their patients.
PROPEL SINUS IMPLANT
Used in conjunction with FESS and/or balloon sinuplasty, the PROPEL sinus implant is a dissolvable, drug-eluting stent that is placed in the sinus passageways to improve outcomes for chronic sinusitis sufferers. It’s two-in-one mechanism helps solve two of the most common issues that surgeons struggle with following surgery and balloon sinuplasty- keeping the airways open for as long as possible and ensuring topical medications can reach the tissue that needs it. The stenting mechanism of PROPEL helps your sinuses maintain an open airway during the healing process, and the localized drug delivery mechanism provides an anti-inflammatory steroid, mometasone furoate, directly to the sinus tissue that needs to be managed. PROPEL helps ensure your surgeon’s clinical outcomes, allowing you to feel better, longer.
Approved by the FDA in 2013, PROPEL is safe and effective and carries fewer risks of patients developing post-surgical scarring or inflammation. The implant, that gradually dissolves, is inserted during an endoscopic sinus procedure or balloon dilation case. It resembles a spring and expands to keep the sinus open, while simultaneously delivering a measured dose of mometasone furoate (an anti-inflammatory steroid) directly to the tissue. The stent itself is completely absorbed by the body four to six weeks after implantation, and the medication stays within the tissue for over 90 days after placement. PROPEL is clinically proven to show improved post-operative outcomes, reducing the need for additional surgical procedures and systemic steroids. This results in more consistently open sinuses and faster healing.
SINUVA – A NON-SURGICAL NASAL POLYP TREATMENT ALTERNATIVE
People who suffer from recurrent nasal polyps understand that it can be a very frustrating disease. Many patients have undergone surgery multiple times to remove the polyps, only to find them return months to years later due to the chronic nature of the disease state. Now there is a new solution for patients suffering from recurrent nasal polyps in Raleigh, Cary, Holly Springs, and surrounding areas in North Carolina. For patients that have had previous ethmoid sinus surgery and suffer from chronic nasal polyps, Mann ENT is proud to offer their patients SINUVA, the latest in non-surgical and minimally invasive options to help manage symptoms from nasal polyps and give patients a break from systemic steroids and surgeries.
What is SINUVA?
SINUVA is a drug-eluting sinus implant proven to reduce polyps, nasal congestion, and obstruction without the need of having another surgery. The long-lasting implant is placed during a routine office visit and stays in the sinus cavity for up to 90 days. Over the 3 months, an anti-inflammatory medication called mometasone furoate is delivered directly to the sinuses, shrinking the nasal polyps for 3-4 months or longer. The simple and effective procedure also improves symptoms such as sinus headaches, nasal
congestion, and loss of smell and taste caused by nasal polyps. It also decreases the chance of needing a repeat sinus surgery compared to patients that don’t receive SINUVA. After approximately 90 days, it is
removed. Being minimally invasive, the patient is able to return to normal behavior immediately with no downtime!
SINUVA Safety & Risks
The safety of SINUVA was established with 400 patients over two clinical trials. Some side-effects observed in clinical studies were bronchitis, upper respiratory or middle ear infection, headache, lightheadedness, asthma, and nose bleed. The risks from SINUVA are similar to those associated with other endoscopic sinus procedures, such as nose bleed, injuries to blood vessels, and bacterial infection. SINUVA is not for people with hypersensitivity to corticosteroids or those with nasal ulcers or trauma.